Comparative Pharmacology
Head-to-head clinical analysis: CO LAV versus TRILYTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO LAV versus TRILYTE.
CO-LAV vs TRILYTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
TRILYTE (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid) is an osmotic laxative. The active components induce diarrhea by osmotically drawing water into the gastrointestinal lumen, thereby increasing stool volume and stimulating peristalsis. Sodium ascorbate and ascorbic acid enhance the osmotic effect.
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
Adults: 1 liter (L) orally every 10-15 minutes until 4 L total consumed; complete ingestion within 4 hours.
None Documented
None Documented
Unknown
Not applicable; non-absorbed, acts locally in GI tract
CO-LAV is not a recognized drug. Please check the drug name.
Renal excretion of intact electrolyte ions; negligible drug excretion
Category C
Category C
Laxative/Bowel Evacuant
Laxative